The efficacy and safety of botulinum toxin type B on digital ulcers in patients with systemic sclerosis

The efficacy and safety of botulinum toxin type B on digital ulcers in patients with systemic sclerosis - The efficacy and safety of BTX-B on digital ulcers in patients with SSc

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024818

Enrollment

Registered

2016-11-14

Start date

2016-12-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

digital ulcers in systemic sclerosis patients

Interventions

placebo subcutaneously injection into hands with digital ulcers botulinum toxin type B subcutaneously injection into hands with digital ulcers

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients fulfilled the criteria of SSc proposed by the American College of Rheumatology and the American College of Rheumatology/European League Against Rheumatism classification criteria. SSc patients with digital ulcers

Exclusion criteria

Exclusion criteria: Patients under the age 18, with the pregnancy or having the past medical histories with BTX were excluded.

Design outcomes

Primary

Measure	Time frame
The rate of the patients which digital ulcer was healed by BTX-B at 8 weeks after treatment compared with that treated with placebo control.	—

Countries

Japan

Contacts

Public ContactSei-ichiro Motegi

Gunma University Graduate School of Medicine Department of Dermatology

gunmaciru-office@umin.ac.jp027-220-8284

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026